Core Framework & Diagram Mast Cells: The Allergy Bomb
7 月 27, 20261 Min Read How Do Immune Cells Fight Together?
7 月 27, 2026Mast cells are the initiators of allergic reactions — once triggered, they instantly release massive inflammatory substances
—— From hay fever to anaphylaxis, these cells stand guard at every entry point of the body.
I. Sentinels standing guard at every entrance — mast cells never enter blood
Most immune cells spend their lives patrolling in blood, migrating to tissues when they sense signals. Mast cells are different.
Mast cells are tissue-resident cells — after emerging from progenitor cells in bone marrow, they migrate to nearly all peripheral tissues and then permanently reside there, never returning to blood. Their deployment strategy is extremely precise: the highest densities of mast cells concentrate in skin, airway mucosa (nasal passages, trachea, lungs), digestive tract mucosa, urinary and reproductive tracts, and around blood vessels — in other words, concentrated everywhere the 'interface between external world and body interior' exists. These are all the most likely points of pathogen invasion.
This strategic deployment has two layers of significance. First, once pathogens breach skin or mucosal barriers, the first immune cells waiting for them are local mast cells — they don't need to rush from blood, they're already on site. Second, mast cells' high-density distribution creates an immune alarm network covering all body entrances — almost any invasion will first trigger local mast cells.
This network's 'trigger' is the IgE antibodies carried on their surface.
2. From B cell to IgE to mast cell: the complete chain of an allergic reaction
To truly understand how allergic reactions develop, you need to connect several components covered in previous articles and see the complete chain.
Step one: Th2-type immune response is (incorrectly) activated. An allergen (pollen protein, peanut protein, dust mite metabolite) is processed by dendritic cells in a 'dangerous' way, activating CD4+ T cells into Th2 differentiation, beginning to secrete IL-4 and IL-13.
Step two: B cells produce IgE. Under Th2 cell-provided IL-4 signals, B cells 'class switch' what would have been an IgG response to producing IgE — specifically targeting this particular allergen.
Step three: IgE arms mast cells and basophils. Produced IgE antibodies are immediately 'captured' by FcεRI receptors on mast cell (and blood basophil) surfaces, firmly binding there. The cell is now in 'armed state' — carrying allergen-specific IgE, ready at any moment to react to this allergen.
Step four: re-exposure triggers degranulation. When the same allergen enters again, it simultaneously binds to multiple adjacent IgE molecules on the mast cell surface, 'cross-linking' them. This cross-linking transmits a powerful activation signal into the mast cell, triggering degranulation: within seconds, intracellular stored granules massively fuse with the cell membrane, releasing granule contents all at once into the extracellular environment.
3. Immediate phase and late-phase reactions: two stages of a single allergic response
Immediate phase reaction
Occurs within seconds to tens of minutes after allergen contact, primarily caused by preformed mediators released by degranulation — substances stored in granules before the allergic reaction, available for immediate release without new synthesis time. Histamine is the most important: acting on H1 receptors on vascular endothelium causing vasodilation (skin redness), increased vascular permeability (tissue edema), and nerve ending stimulation (itch); in nasal mucosa causing runny nose and congestion. Tryptase is a mast cell-specific marker of degranulation, clinically used to diagnose anaphylaxis.
Late-phase reaction
Occurs four to twelve hours after allergen contact, primarily caused by lipid mediators and cytokines newly synthesized after mast cell activation. Leukotrienes (LTC4, LTD4) and prostaglandins (PGD2) play major roles: leukotrienes cause persistent airway contraction and increased mucus secretion; PGD2 recruits eosinophils into the airway. The TNF-α, IL-4, IL-5, and IL-13 secreted by mast cells drive sustained airway mucosal inflammation lasting hours to days. The asthma patient's familiar 'nighttime worsening' often reflects the late-phase reaction — daytime allergen exposure, late-phase inflammation peaking at night with heaviest airway symptoms.
4. Mast cells' positive value: they're not just trouble-makers
In the discussions above, mast cells have only appeared as allergy 'villains.' That's unfair — like eosinophils, mast cells evolved to handle real threats.
Mast cells play important roles in fighting bacterial infections. Their surface carries not only IgE receptors but also pattern recognition receptors that identify bacterial components (like TLR4, recognizing bacterial LPS). Activated by bacteria, mast cells release pro-inflammatory cytokines, recruiting neutrophils and macrophages to the infection site — important early signals for initiating local bacterial infection responses. Mice lacking mast cells show significantly lower survival rates in peritonitis models, demonstrating their indispensability in anti-bacterial infection.
Mast cells also play important roles in venom defense. Snake and bee venom contain certain proteases that can directly activate mast cell degranulation, triggering local and systemic inflammatory responses. The original function: using rapid inflammatory response to 'flush' toxins, while vasodilation increases toxin excretion.
5. Mast cell treatment targets: from antihistamines to monoclonal antibodies
Understanding mast cell activation mechanisms lets us see the action targets of existing allergy drugs more clearly.
First-line defense — stabilizing mast cells, preventing degranulation: sodium cromoglicate stabilizes mast cell membranes, inhibiting calcium ion influx and preventing degranulation — a strategy of 'defusing the bomb before it explodes.' Effective for preventive treatment of asthma and allergic rhinitis, particularly suitable for preventive use before known allergen exposure.
Second line — blocking released mediators: H1 receptor antagonists (first-generation diphenhydramine, second-generation cetirizine, loratadine) block histamine H1 receptors, reducing immediate-phase allergy symptoms. Leukotriene receptor antagonists (montelukast) block LTD4 receptors, effective for late-phase reactions and asthma.
Third line — targeting IgE, cutting off the activation signal at the source: omalizumab (anti-IgE monoclonal antibody) binds free IgE, preventing IgE from binding to mast cell surface FcεRI receptors, fundamentally reducing the amount of allergen-specific IgE armed onto mast cells, lowering mast cell trigger sensitivity. This is the most important targeted biological therapy for allergic asthma and chronic urticaria, and currently the most evidence-backed mast cell targeting strategy.
Fourth line — desensitization treatment (specific immunotherapy): through retraining Th1/Treg responses, fundamentally changes the body's immune response pattern to allergens — the only treatment that can change the allergy immune mechanism rather than just controlling symptoms.
Frequently Asked Questions